Drug lookup | Fillwise

Apo-Rivaroxaban · DIN 02541734 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Rivaroxaban · DIN 02541734 Manufacturer: Apotex Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand APO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103036 · Verify on the e-Formulary ↗ (DIN 02541734)

Source record

DIN 02541734: Apo-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541734 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103036

Interchangeable products

Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541734

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Rivaroxaban · DIN 02549328 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Bio-Rivaroxaban · DIN 02549328 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2025-01-14 · brand BIO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Biomed pharma · schedule Prescription

Check this DIN again · Health Canada product record

Bio-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103818 · Verify on the e-Formulary ↗ (DIN 02549328)

Source record

DIN 02549328: Bio-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id BMP Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549328 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103818

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549328

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Rivaroxaban · DIN 02553368 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Rivaroxaban · DIN 02553368 Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29 Health Canada: Marketed since 2025-06-10 · brand JAMP RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104230 · Verify on the e-Formulary ↗ (DIN 02553368)

Source record

DIN 02553368: Jamp Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id JPC Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553368 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104230

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553368

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Rivaroxaban · DIN 02551608 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

M-Rivaroxaban · DIN 02551608 Manufacturer: Mantra Pharma Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-12-19 · brand M-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104033 · Verify on the e-Formulary ↗ (DIN 02551608)

Source record

DIN 02551608: M-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id MAT Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02551608 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104033

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551608

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Rivaroxaban · DIN 02527537 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Rivaroxaban · DIN 02527537 Manufacturer: Pharmascience Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand PMS-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101660 · Verify on the e-Formulary ↗ (DIN 02527537)

Source record

DIN 02527537: PMS-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id PMS Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527537 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101660

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527537

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reddy-Rivaroxaban · DIN 02524503 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Reddy-Rivaroxaban · DIN 02524503 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand REDDY-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Dr reddy's laboratories ltd · schedule Prescription

Check this DIN again · Health Canada product record

Reddy-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101353 · Verify on the e-Formulary ↗ (DIN 02524503)

Source record

DIN 02524503: Reddy-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id DRR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524503 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101353

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524503

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rivaroxaban · DIN 02541467 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rivaroxaban · DIN 02541467 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-01-31 Health Canada: Marketed since 2023-11-08 · brand RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103011 · Verify on the e-Formulary ↗ (DIN 02541467)

Source record

DIN 02541467: Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id SIV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541467 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103011

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541467

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rivaroxaban · DIN 02547899 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rivaroxaban · DIN 02547899 Manufacturer: Sanis Health Inc.; listing date 2025-03-31 Health Canada: Marketed since 2024-12-13 · brand RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103681 · Verify on the e-Formulary ↗ (DIN 02547899)

Source record

DIN 02547899: Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id SAI Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103681

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547899

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Rivaroxaban · DIN 02537877 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Rivaroxaban · DIN 02537877 Manufacturer: Sandoz Canada Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand SANDOZ RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102663 · Verify on the e-Formulary ↗ (DIN 02537877)

Source record

DIN 02537877: Sandoz Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id SDZ Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102663

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: resolved shortage (ended 2025-06-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02537877

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Rivaroxaban · DIN 02526786 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Taro-Rivaroxaban · DIN 02526786 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand TARO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Taro pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Taro-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101584 · Verify on the e-Formulary ↗ (DIN 02526786)

Source record

DIN 02526786: Taro-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id TAR Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02526786 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101584

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: resolved shortage (ended 2026-05-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02526786

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Rivaroxaban · DIN 02547295 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Rivaroxaban · DIN 02547295 Manufacturer: Teva Canada Limited; listing date 2025-03-31 Health Canada: Marketed since 2024-11-26 · brand TEVA-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Rivaroxaban: Formulary list price $0.3550/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103592 · Verify on the e-Formulary ↗ (DIN 02547295)

Source record

DIN 02547295: Teva-Rivaroxaban Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $0.3550; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547295 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103592

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Xarelto · DIN 02480808 · $0.3550

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547295

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xarelto · DIN 02480808 · 2.5mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: innoviCares lists Xarelto (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

Savings card: RxHelp ONE lists Xarelto (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)

1 brand, same coverage

Xarelto · DIN 02480808 Manufacturer: Bayer Inc., Health Care Division; listing date 2019-12-20 Health Canada: Marketed since 2018-09-28 · brand XARELTO · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 2.5 MG · company Bayer inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3550 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97146 · Verify on the e-Formulary ↗ (DIN 02480808)

Source record

DIN 02480808: Xarelto Raw flags: sec3=Y Item: 201200104; group id 259; item number 0506; lccId None; manufacturer id BAH Source form: Tab; strength: 2.5mg Recorded listing: General benefit Source prices (unrounded): $1.4200; ministry $0.3550 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02480808 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97146

Interchangeable products

Apo-Rivaroxaban · DIN 02541734 · $0.3550 Bio-Rivaroxaban · DIN 02549328 · $0.3550 Jamp Rivaroxaban · DIN 02553368 · $0.3550 M-Rivaroxaban · DIN 02551608 · $0.3550 PMS-Rivaroxaban · DIN 02527537 · $0.3550 Reddy-Rivaroxaban · DIN 02524503 · $0.3550 Rivaroxaban · DIN 02541467 · $0.3550 Rivaroxaban · DIN 02547899 · $0.3550 Sandoz Rivaroxaban · DIN 02537877 · $0.3550 Taro-Rivaroxaban · DIN 02526786 · $0.3550 Teva-Rivaroxaban · DIN 02547295 · $0.3550

Shortage status: resolved shortage (ended 2021-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02480808

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Rivaroxaban · DIN 02470497 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Rivaroxaban · DIN 02470497 Manufacturer: Apotex Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand APO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95947 · Verify on the e-Formulary ↗ (DIN 02470497)

Source record

DIN 02470497: Apo-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470497 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95947

Interchangeable products

Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: shortage reported ended 2026-06-11 (report last updated 2026-06-11); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02470497

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Rivaroxaban · DIN 02549336 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Bio-Rivaroxaban · DIN 02549336 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2025-01-14 · brand BIO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Biomed pharma · schedule Prescription

Check this DIN again · Health Canada product record

Bio-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103819 · Verify on the e-Formulary ↗ (DIN 02549336)

Source record

DIN 02549336: Bio-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id BMP Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549336 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103819

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549336

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Rivaroxaban · DIN 02516292 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Rivaroxaban · DIN 02516292 Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30 Health Canada: Marketed since 2024-02-05 · brand JAMP RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100565 · Verify on the e-Formulary ↗ (DIN 02516292)

Source record

DIN 02516292: Jamp Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02516292 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100565

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02516292

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Rivaroxaban · DIN 02551616 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

M-Rivaroxaban · DIN 02551616 Manufacturer: Mantra Pharma Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-12-19 · brand M-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104034 · Verify on the e-Formulary ↗ (DIN 02551616)

Source record

DIN 02551616: M-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id MAT Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02551616 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104034

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: resolved shortage (ended 2026-07-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02551616

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Rivaroxaban · DIN 02512041 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Rivaroxaban · DIN 02512041 Manufacturer: Pharmascience Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand PMS-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100127 · Verify on the e-Formulary ↗ (DIN 02512041)

Source record

DIN 02512041: PMS-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512041 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100127

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512041

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reddy-Rivaroxaban · DIN 02472414 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Reddy-Rivaroxaban · DIN 02472414 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand REDDY-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Dr reddy's laboratories ltd · schedule Prescription

Check this DIN again · Health Canada product record

Reddy-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96172 · Verify on the e-Formulary ↗ (DIN 02472414)

Source record

DIN 02472414: Reddy-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id DRR Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472414 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96172

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02472414

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rivaroxaban · DIN 02541475 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rivaroxaban · DIN 02541475 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2024-01-31 Health Canada: Marketed since 2023-11-08 · brand RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription

Check this DIN again · Health Canada product record

Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103012 · Verify on the e-Formulary ↗ (DIN 02541475)

Source record

DIN 02541475: Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541475 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103012

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541475

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Rivaroxaban · DIN 02547902 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Rivaroxaban · DIN 02547902 Manufacturer: Sanis Health Inc.; listing date 2025-03-31 Health Canada: Marketed since 2024-12-13 · brand RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103682 · Verify on the e-Formulary ↗ (DIN 02547902)

Source record

DIN 02547902: Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547902 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103682

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547902

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Rivaroxaban · DIN 02482223 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Rivaroxaban · DIN 02482223 Manufacturer: Sandoz Canada Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand SANDOZ RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97270 · Verify on the e-Formulary ↗ (DIN 02482223)

Source record

DIN 02482223: Sandoz Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id SDZ Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482223 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97270

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: resolved shortage (ended 2026-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482223

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Rivaroxaban · DIN 02483807 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Taro-Rivaroxaban · DIN 02483807 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand TARO-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Taro pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Taro-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97416 · Verify on the e-Formulary ↗ (DIN 02483807)

Source record

DIN 02483807: Taro-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id TAR Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483807 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97416

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: resolved shortage (ended 2025-11-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483807

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Rivaroxaban · DIN 02507196 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Rivaroxaban · DIN 02507196 Manufacturer: Teva Canada Limited; listing date 2023-12-29 Health Canada: Marketed since 2023-11-01 · brand TEVA-RIVAROXABAN · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Rivaroxaban: Formulary list price $0.7175/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99659 · Verify on the e-Formulary ↗ (DIN 02507196)

Source record

DIN 02507196: Teva-Rivaroxaban Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7175; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507196 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99659

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Xarelto · DIN 02316986 · $0.7175

Shortage status: active shortage (reported 2025-06-10, estimated to end 2026-11-30, last updated 2026-06-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507196

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xarelto · DIN 02316986 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: innoviCares lists Xarelto (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

Savings card: RxHelp ONE lists Xarelto (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)

1 brand, same coverage

Xarelto · DIN 02316986 Manufacturer: Bayer Inc., Health Care Division; listing date 2009-06-23 Health Canada: Marketed since 2008-09-16 · brand XARELTO · ATC B01AF01 RIVAROXABAN · form Tablet · route Oral · ingredients RIVAROXABAN 10 MG · company Bayer inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.7175 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80247 · Verify on the e-Formulary ↗ (DIN 02316986)

Source record

DIN 02316986: Xarelto Raw flags: sec3=Y Item: 201200079; group id 259; item number 0507; lccId None; manufacturer id BAH Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $2.8700; ministry $0.7175 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02316986 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80247

Interchangeable products

Apo-Rivaroxaban · DIN 02470497 · $0.7175 Bio-Rivaroxaban · DIN 02549336 · $0.7175 Jamp Rivaroxaban · DIN 02516292 · $0.7175 M-Rivaroxaban · DIN 02551616 · $0.7175 PMS-Rivaroxaban · DIN 02512041 · $0.7175 Reddy-Rivaroxaban · DIN 02472414 · $0.7175 Rivaroxaban · DIN 02541475 · $0.7175 Rivaroxaban · DIN 02547902 · $0.7175 Sandoz Rivaroxaban · DIN 02482223 · $0.7175 Taro-Rivaroxaban · DIN 02483807 · $0.7175 Teva-Rivaroxaban · DIN 02507196 · $0.7175

Shortage status: resolved shortage (ended 2025-08-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02316986

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

RIVAROXABAN

Apo-Rivaroxaban · DIN 02541734 · 2.5mg · tablet

Bio-Rivaroxaban · DIN 02549328 · 2.5mg · tablet

Jamp Rivaroxaban · DIN 02553368 · 2.5mg · tablet

M-Rivaroxaban · DIN 02551608 · 2.5mg · tablet

PMS-Rivaroxaban · DIN 02527537 · 2.5mg · tablet

Reddy-Rivaroxaban · DIN 02524503 · 2.5mg · tablet

Rivaroxaban · DIN 02541467 · 2.5mg · tablet

Rivaroxaban · DIN 02547899 · 2.5mg · tablet

Sandoz Rivaroxaban · DIN 02537877 · 2.5mg · tablet

Taro-Rivaroxaban · DIN 02526786 · 2.5mg · tablet

Teva-Rivaroxaban · DIN 02547295 · 2.5mg · tablet

Xarelto · DIN 02480808 · 2.5mg · tablet

Apo-Rivaroxaban · DIN 02470497 · 10mg · tablet

Bio-Rivaroxaban · DIN 02549336 · 10mg · tablet

Jamp Rivaroxaban · DIN 02516292 · 10mg · tablet

M-Rivaroxaban · DIN 02551616 · 10mg · tablet

PMS-Rivaroxaban · DIN 02512041 · 10mg · tablet

Reddy-Rivaroxaban · DIN 02472414 · 10mg · tablet

Rivaroxaban · DIN 02541475 · 10mg · tablet

Rivaroxaban · DIN 02547902 · 10mg · tablet

Sandoz Rivaroxaban · DIN 02482223 · 10mg · tablet

Taro-Rivaroxaban · DIN 02483807 · 10mg · tablet

Teva-Rivaroxaban · DIN 02507196 · 10mg · tablet

Xarelto · DIN 02316986 · 10mg · tablet

Matched class: 20:12 Coagulants and Anti-Coagulants

APIXABAN

DABIGATRAN ETEXILATE

ENOXAPARIN

WARFARIN

DALTEPARIN SODIUM

FONDAPARINUX SODIUM

NADROPARIN CALCIUM

TICAGRELOR

TINZAPARIN SODIUM

EPTIFIBATIDE

EDOXABAN

TRANEXAMIC ACID

Availability